A shift in focus to research and development of novel ICIs which target antigens that are not shared amongst both the myocardium and tumor in question, unlike the current targets PD-1, PD-L1, CTLA-4, and LAG-3 may limit inflammatory reactions against cardiomyocytes. This evidence concerns the gene PDCD1 and neoplasm.